NDAORALTABLET
Approved
Sep 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQUATENSEN (methyclothiazide) is an oral thiazide diuretic approved in 1977 for the treatment of hypertension and edema. It functions as a mild diuretic and antihypertensive agent by promoting sodium and water excretion. The drug is a legacy small molecule indicated for patients requiring blood pressure control or fluid management.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the commercial footprint is expected to contract, indicating smaller brand teams and reduced headcount growth potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AQUATENSEN offers limited career advancement potential given its mature market position, approaching LOE, and zero linked job openings. This assignment is suited for professionals managing legacy products or those seeking stable, low-growth portfolio roles with Bausch Health.
Brand ManagerField Sales Representative
Worked on AQUATENSEN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.